The DOI matches its Crossref record.
Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer
Open accessAbstract
BACKGROUND: Sequential treatment with azacitidine can induce re‐expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b‐2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer. METHODS: Patients with pathologically confirmed intermediate‐grade or high‐grade epithelial ovarian cancer who developed disease progression within 6 months (resistant disease, n = 18 patients) or during a platinum‐based therapy (refractory disease, n = 12 patients) were eligible. All patients had measurable disease. RESULTS: Thirty patients received a total of 163 cycles of treatment. This regimen produced 1 complete response, 3 partial responses (overall response rate [ORR], 13.8%), and 10 cases of stable disease among 29 evaluable patients. For those patients who achieved clinical benefits, the median duration of the treatment was 7.5 months. The median progression‐free survival (PFS) and overall survival (OS) for all patients were 3.7 months and 14 months, respectively. Patients with platinum‐resistant disease achieved an ORR of 22%, with a median PFS of 5.6 months and a median OS of 23 months. The predominant toxicities were fatigue and myelosuppression. Correlative studies indicated that DR4 methylation in peripheral blood leukocytes was decreased during treatment in 3 of 4 objective responders (75%), but in only 5 of 13 nonresponders (38%). CONCLUSIONS: To the authors' knowledge, the results of the current study provide the first clinical evidence that a hypomethylating agent may partially reverse platinum resistance in patients with ovarian cancer. Further clinical evaluation of hypomethylating agents in combination with carboplatin is warranted. Cancer 2011. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
“In that study (38), a higher dose (75 mg/m(2)/d) of the hypomethylating agent was administered, largely necessary because of diminished stability of azacytidine caused by addi-”
Epigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Epigenetics as a Therapeutic Target in Breast Cancer
Connolly, R., & Stearns, V. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9263-3 · Cited by 117
Metadata
- Authors
- Fu, S., Hu, W., Iyer, R., Kavanagh, J. J., Coleman, R. L., Levenback, C. F., Sood, A. K., Wolf, J. K., Gershenson, D. M., Markman, M., Hennessy, B. T., Kurzrock, R., & Bast, R. C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-11-08
- Volume
- 117
- Issue
- 8
- Pages
- 1661-1669
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1997981312
- Cited by
- 183
- References
- 0
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.